摘要
目的观察血压达标对中、重度高血压患者C反应蛋白和尿微量白蛋白的影响。方法随机选取85例中、重度原发性高血压患者,分为血压达标组55例,未达标组30例,每天给硝苯地平控释片30mg和氯沙坦钾50mg。分别比较血压达标与未达标患者治疗前后的C反应蛋白、尿微量白蛋白、血尿素氮、肌酐、尿酸及不良反应。结果两组C反应蛋白和尿微量白蛋白均有下降(P<0.01或P<0.05),与未达标组相比,达标组C反应蛋白及尿微量白蛋白下降更为明显(P<0.01)。结论血压达标对高血压患者的获益部分可能通过抗炎、降低尿微量白蛋白作用实现。
Objective To investigate the effects of decreasing blood pressure to the goal on C-reactive protein and microalbuminuria in patients with morderate or severe essential hypertension. Methods We randomly selected 85 patients with morderate or severe essential hypertension, at the same time, gave them both Nifedipine controlled-release tablets (30mg qd) and Losartan (50mg qd). Compared C-reactive protein, microalbuminuria, blood ureanitrogen, createine, uric acid and adverse reaction of the patients up to the standard or not respectively, before and after treatment. Results The number of the patients,whose blood pressure up to the standard was 55, the left was 30. Both of C-reactive protein and microalbuminuria were reduced significantly (P 〈 0.01 或 P 〈 0.05 ). In contrast, C-reactive protein and microalbuminuria in the group with lowering blood pressure to the goal comparing to the group without to the goal were much more lower (P 〈 0.01 ). Conclusion Patients with essential hypertension profit from the blood pressure up to the standard mybe partly achieve by anti-inflammatory, reducing the role of microalbuminuria.
出处
《中国现代医生》
2011年第29期30-31,共2页
China Modern Doctor